Literature DB >> 12202538

Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells.

Philip L Penfold1, Li Wen, Michele C Madigan, Nicholas J C King, Jan M Provis.   

Abstract

PURPOSE: The therapeutic potential of TA, an anti-inflammatory glucocorticoid, for the treatment of exudative retinopathy has been examined in several independent clinical studies. The modulation of permeability and adhesion molecule expression of an epithelial cell line has been described in vitro, with the use of cytokines and triamcinolone acetonide (TA). In the current study, the influence of proinflammatory cytokines and TA on permeability and adhesion molecule expression in human choroidal endothelial cells (CECs) was investigated.
METHODS: Human CEC isolates treated with IFNgamma, TNFalpha, and TA were evaluated by flow cytometry and immunocytochemistry for expression of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and major histocompatibility complex (MHC)-I and -II. The effects of IFNgamma, TNFalpha, and TA on paracellular permeability of CEC monolayers were assessed in transendothelial cell resistance (TER) assays.
RESULTS: Both IFNgamma and TNFalpha significantly upregulated expression of ICAM1 and MHC-I on CECs. Expression of VCAM1 was induced after stimulation with both IFNgamma and TNFalpha, whereas expression of MHC-II was induced only by stimulation with IFNgamma. Cytokine-induced expression of ICAM1, MHC-I, and MHC-II antigen by CECs was significantly downregulated by TA. IFNgamma stimulation also increased permeability of CEC monolayers, whereas subsequent TA treatment decreased permeability of CEC monolayers.
CONCLUSIONS: Human CEC isolates provide a useful in vitro model to study choroidal neovascular membrane characteristics and their potential response to pro- and anti-inflammatory agents. In addition, the results indicate that TA has the capacity to reduce adhesion molecule expression and permeability of choroidal vessels in vitro, confirming its potential as a therapeutic agent for treatment of exudative macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202538

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

Review 2.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

3.  Isolation, culture, and characterisation of human macular inner choroidal microvascular endothelial cells.

Authors:  A C Browning; T Gray; W M Amoaku
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

Review 4.  Current approaches to the management of diabetic retinopathy and diabetic macular oedema.

Authors:  Francesco Boscia
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

5.  Visual improvement following trans-Tenon's retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy.

Authors:  Akiko Okubo; Motoko Ito; Taro Kamisasanuki; Taiji Sakamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-11       Impact factor: 3.117

6.  One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Authors:  Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2012-09-19       Impact factor: 2.447

7.  Effect of Methyl-CpG binding domain protein 2 (MBD2) on AMD-like lesions in ApoE-deficient mice.

Authors:  Jun-Ru Pan; Chen Wang; Qi-Lin Yu; Shu Zhang; Bin Li; Jun Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

8.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.

Authors:  W-M Chan; T Y Y Lai; A L Wong; J-P Tong; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

Review 9.  Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration.

Authors:  Lekha Gopal; Tarun Sharma
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

10.  Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.

Authors:  Fatemeh Valamanesh; Marianne Berdugo; Florian Sennlaub; Michèle Savoldelli; Cyndie Goumeaux; Marianne Houssier; Jean-Claude Jeanny; Alicia Torriglia; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.